All In Biotech

Drug Trial Radar · NCT00454662

Combination of OLMesartan and CCB or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)

Combination of OLMesartan and Calcium Channel Blocker or Low Dose Diuretics in High Risk Elderly Hypertensive Patients Study (COLM-Study)

Last checked: Nov 20, 2026Latest source record: Jan 23, 2013 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 5,141 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

5,141

Actual

Start

Apr 2007

Primary completion

Sep 2011

Study completion Sep 2011

Sponsor

Lead sponsor
COLM Study Research OrganizationAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Japan Heart Foundation
First posted
Apr 2, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Prevention
Who can join
All sexes, from 65 years, up to 84 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to investigate which combination therapy is more effective in reducing the incidence of cardiovascular events in Japanese elderly high-risk hypertensive patients: AT1 subtype angiotensin II receptor antagonist/calcium channel blocker or AT1 subtype angiotensin II receptor antagonist/low dose diuretic.

Conditions

  • Hypertension
  • Cardiovascular Disease
  • Diabetes

Interventions

  • olmesartan medoxomil / amlodipine or azelnidipineDrug

    AT1 subtype angiotensin II receptor antagonist / calcium channel blocker : 5-40mg of olmesartan medoxomil / 2.5-5mg of amlodipine or 8-16mg of azelnidipine

  • olmesartan medoxomil / low dose thiazide type drugDrug

    AT1 subtype angiotensin II receptor antagonist / low dose diuretic : 5-40mg of olmesartan medoxomil / low dose thiazide type drug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Composite of following events: Sudden death, Cerebrovascular events, Coronary events, Renal dysfunctionTime frame: 3 to 4.5 years (duration of planned treatment phase)

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • COLM-Study Data Center

    Kamiyacho Mount Bld.14F, 4-3-20 Toranomon Minato-ku, Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.